Shares in Virbac (VIRB.PA) jump 3% after the company reported a strong revenue growth in Q1 driven by strategic “supercharge” platforms, and maintained 2026 guidance
The French animal health company published Q1 revenue at 384 million euros ($452.31 million), up 7.7% yoy at constant exchange rate and scope
“Growth is largely driven by the strategic “Supercharge” platforms, which group together the highest value-added franchises of the group (therapeutic nutrition, reproduction, dental, mobility, otology, endocrinology — strengthened by Thyronorm — and ruminants), says TP ICAP Midcap
The broker adds these platforms are growing by around +15% at constant FX and constitute the main structural engine of the organic growth and value-creation trajectory for the group
Jefferies also flags North America leads regional growth at 20.7%, boosted by momentum in mobility, dental and ear product categories as well as a strong ramp-up of the Thyronorm acquisition
It notes that foreign exchange remains a material headwind, weighing approximately 5.5% on reported growth in the quarter
Management reiterates its full-year 2026 guidance, saying the strong first-quarter performance “continued to give confidence” in its annual targets
Including today’s gains, the stock is up 4.2% year-to-date ($1 = 0.8490 euros)

ARKG

Reuters

SPDR S&P Health Equip

Ark Genomic Revolution ETF

iShares US Pharma

VanEck Biotech ETF

iShares US Medical Devices

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

Health Care Select Sector SPDR

ChinaAMC CSI All Share Health Care Devices ETF

Proshares Ultra Nasdaq Biotech

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

Proshares UltraShort Nasdaq Biotech

China Merchants CSI All Share Medical Apparatus and Instruments ETF

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

VG Health

ALPS Medical Breakthrough

iShares Global Healthcare

TP ICAP Group plc

Jefferies Financial

BUZZ-Virbac shares rise on strong Q1 revenue growth